In Vitro Dissolution of Pharmaceutical Solids

Oral Bioavailability: Basic Principles, Advanced Concepts, and Applications

Volumn , Issue , 2011, Pages 39-49

  Soh, Josephine L P ^a   Heng, Paul W S ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Automated sampling automation, good quality control of dissolution data; in vitro in vivo correlation (IVIVC) rational relationship, biological outcome or fate; Pharmaceutical solids' in vitro dissolution active pharmaceutical ingredient (API), rate limiting step

Indexed keywords

EID: 84870227145     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118067598.ch4     Document Type: Chapter

References (45)

1. Aakeröy CB (1997) Crystal engineering: strategies and architectures. Acta Cryst 53:569-586.
2. Adhiyaman R and Basu SK (2006) Crystal modification of dipyridamole using different solvents and crystallisation conditions. Int J Pharm 321(1-2):27-34.
3. Amidon GL, Lennernas H, Shah VP, and Crison JR (1995) A theoretical basis for a biopharmaceutics drug classification: the correlation of in vivo drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
4. Arima H, Hirayama F, Okamoto CT, and Uekama K (2002) Recent aspects of cyclodextrin-based pharmaceutical formulations. Recent Res Devel Chem Pharm Sci 2:155-193.
5. Azarmi S, Roac W, and Lobenberg R (2007) Current perspectives in dissolution testing of conventional and novel dosage forms. Int J Pharm 328:12-21.
6. Baxter JL, Muzzio FJ, and Kukura J (2004) Shear distribution and variability in the USP apparatus 2 under turbulent conditions. Int J Pharm 279:9-17.
7. Baxter JL, Muzzio FJ, and Kukura J (2005) Hydrodynamicsinduced variability in the USP apparatus II dissolution test. Int J Pharm 292:17-28.
8. Blagden N, de Matas M, Gavan PT, and York P (2007) Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev 59:617-630.
9. Borst I, Ugwu S, and Beckett AH (1997) New and Extended Application for USP Drug Release Apparatus 3. Disso Technol, pp. 1-6.
10. Brunner E (1904) Reaktionsgeschwindigkeit in heterogenen Systemen. Z Phys Chem 43:56-102.
11. Carrier RL, Miller LA, and Ahmed I (2007) The utility of cyclodextrins for enhancing oral bioavailability. J Control Release 123:78-99.
12. Challa R, Ahuja A, Ali J, and Khar RK (2005) Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech 6(2):E329-E357.
13. Chauhan B, Shimpi S, and Paradkar A (2005) Preparation and evaluation of glibenclamidepolyglycolized glycerides solid dispersions with silicon dioxide by spray drying technique. Eur J Pharm Sci 26:219-230.
14. Davis ME and Brewster ME (2004) Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 3:1023-1035.
15. Dong XY, Shi JH, and Sun Y (2002) Cooperative effect of the artificial chaperones and guanidinium chloride on lysozyme renaturation at high concentrations. Biotechnol Prog 18:663-665.
16. Dressman JF and Kramer J (Eds) (2005) Pharmaceutical Dissolution Testing. Informa Healthcare, Florida.
17. Ghebremeskel AN, Vemavarapu C, and Lodaya M. (2007) Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: selection of polymer-surfactant combinations using solubility parameters and testing the processability. Int J Pharm 328:119-129.
18. Greenwood DE (1994) Small Intestinal pH and Buffer Capacity: Implication for Dissolution of Ionisable Compounds. Ph.D thesis, The University of Michigan.
19. Hattori M, Okada Y, and Takahashi K (2000) Functional changes in ß-Lactoglobulin upon conjugation with carboxymethyl cyclodextrin. J Agric Food Chem 48:3789-3794.
20. Healy AM, McCarthy LG, Gallagher KM, and Corrigan OI (2002) Sensitivity of dissolution rate to location in the paddle dissolution apparatus. J Pharm Pharmacol 54:441-444.
21. Heng JYY, Thielmann F, and Williams DR (2006) The effects of milling on the surface properties of form I paracetamol crystals. Pharm Res 23(8):1918-1927.
22. Hixson AW and Crowell JH (1931) Dependence of reaction velocity upon surface and agitation. Ind Eng Chem 23:923-931.
23. Konno H and Taylor LS (2006) Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci 95:2692-2705.
24. Kwei GY, Novak LB, Hettrick LA, Reiss ER, Ostovic D, Loper AE, Lui CY, Higgins RJ, Chen IW, and Lin JH (1995) Regiospecific intestinal-absorption of the HIV protease inhibitor L-735,524 in Beagle dogs. Pharm Res 12:884-888.
25. Miller DA, Gamba M, Sauer D, Purvis TP, Clemens NT, and Williams RO (2007) Evaluation of the USP dissolution test method A for enteric-coated particles by planar laser-induced fluorescence. Int J Pharm 330:61-72.
26. Nernst W (1904) Theorie der Reaktionsgeschwindigkeit in heterogenen systemen. Z Phys Chem 47:52-55.
27. Nokhodchi A, Bolourtchian N, and Dinarvand R (2003) Crystal modification of phenytoin using different solvents and crystallisation conditions. Int J Pharm 250(1):85-97.
28. Noyes AA and Whitney WR (1897) The rate of solution of solid substances in their own solutions. J Am Chem Soc 19:930-934.
29. Otzen DE, Knudsen BR, Aachmann F, Larsen KL, and Wimmer R (1999) Structural basis for cyclodextrins' suppression of human growth hormone aggregation. Protein Sci 11:1779-1787.
30. Remenar JF, Morisette SL, Peterson ML, Moulton B, MacPhee MJ, Guzman HR, and Almarsson O (2003) Crystal engineering of novel co-crystals of a triazole drug with 1,4-dicarboxylic acids. J Am Chem Soc 125:8456-8457.
31. Rodier E, Lochard H, Sauceau M, Letourneau J-J, Freiss B, and Fages J (2005) A three step supercritical process to improve the dissolution rate of Eflucimibe. Eur J Pharm Sci 26:184-193.
32. Sigurjonsdottir JF, Loftsson T, and Masson M (1999) Influence of cyclodextrins on the stability of the peptide salmon calcitonin in aqueous solution. Int J Pharm 186:205-213.
33. Stavchansky R and McGinity J. Bioavailability and tablet technology, in: Pharmaceutical Dosage Forms: Tablets, Volume 2, (Lieberman HA, Lachman L, and Schwartz JB, eds.), Marcel Dekker Inc., New York, 1998, pp. 349-353.
34. Thompson DO (1997) Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. Crit Rev Ther Drug Carr Syst 14(1):1-104.
35. Uekama K and Otagiri M (1987) Cyclodextrins in drug carrier systems. Crit Rev Ther Drug Carr Syst 3(1):1-40.
36. U.S. Food and Drug Administration, Center for Drug Evaluation and Research (1997a) Guidance for Industry: Extended-Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations, Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210, Rockville, MD.
37. U.S. Food and Drug Administration, Center for Drug Evaluation and Research (1997b) Guidance for Industry: Dissolution Testing of Immediate-Release Solid Oral Dosage Forms, Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210, Rockville, MD.
38. U.S. Food and Drug Administration, Center for Drug Evaluation and Research (2000) Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210, Rockville, MD.
39. U.S. Food and Drug Administration, Center for Drug Evaluation and Research (2003) Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations, Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210, Rockville, MD.
40. USP 31 (2008) General Monograph on Dissolution , United States Pharmacopoeia, Volume 31.
41. Vasconcelos T, Sarmento B, and Costa P (2007) Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Disc Today 12(23/24):1068-1075.
42. Wagner JG (1970) Rate of dissolution in vivo and in vitro, Part II. Drug Intell. Clin Pharm 4:32.
43. Yang L (2008) Biorelevant dissolution testing of colon-specific delivery systems activated by colonic microflora. J Control Release 125:77-86.
44. Yu LX and Amidon GL. (1999) Analytical solutions to mass transfer, in: Transport Processes in Pharmaceutical Systems, Volume 102 (Amidon GL, Lee PI, and Topp EM, eds.), Marcel Dekker Inc., New York, pp. 23-54.
45. Yu LX, Wang JT, and Hussain AS (2002) Evaluation of USP apparatus 3 for dissolution testing of immediate-release products. AAPS PharmSci 4(1): Article 1.